M. Rouyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
M. Rouyer has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
D. Smith
University Hospital, Bordeaux, France
5 shared publicationsN. Moore
Université de Bordeaux, Bordeaux, France
4 shared publicationsA. Fourrier-Réglat
3 shared publicationsA. Ravaud
CHU de Bordeaux, Bordeaux, France; Service de Pharmacologie, Universitá V Segalen, Bordeaux, France; Universitá Victor Segalen, Bordeaux, France; Clinique Callabet, Agen, France; Clinique de l'Union, Toulouse, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Centre Hospitalier Universitaire Saint Andrá, Bordeaux, France; Universite V Segalen Service de Pharmacologie, Bordeaux, France; Service de Pharmacologie, Universitá de Bordeaux, Bordeaux, France
3 shared publicationsP. Noize
CHU de Bordeaux, Bordeaux, France
3 shared publicationsA. Balestra
Université de Bordeaux, Bordeaux, France
2 shared publications
Latest Publications
- Open Access
- 1 June 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, ii6
Real-Life Use of Cetuximab in 1st-Line Treatment of Unresectable Metastatic Colorectal Cancer (MCRC) and Outcomes After Surgical Resection of Metastases: Updated Data from the Erebus Cohort
- 1 June 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, ii6
Open AccessReal-Life Use of Cetuximab in 1st-Line Treatment of Unresectable Metastatic Colorectal Cancer (MCRC) and Outcomes After Surgical Resection of Metastases: Updated Data from the Erebus Cohort
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e14094
Use of cetuximab in a real-life setting in France with respect to KRAS status: Preliminary results of EREBUS cohort study.
E14094 Background: Cetuximab demonstrated survival outcome improvement in metastatic colorectal cancer (mCRC). Cetuximab was first launched as a second-line therapy in mCRC. In July 2008, this indication was extended to first-line therapy and restricted to mCRC patients with wild-type (wt) KRAS gene. We present here the preliminary results of the French EREBUS cohort study to describe cetuximab prescription patterns according to KRAS status in a real-life setting. Methods: EREBUS is a cohort study conducted in 93 French centres. Patients initiating cetuximab between Jan and Dec 2009 were identified from nominative hospital pharmacy dispensations. The cohort included mCRC patients treated in first-line were followed for 12 months to evaluate the rate of metastases resection, usage patterns, safety and effectiveness of cetuximab. Results: To date, 1044 patients treated by cetuximab for colorectal cancer have been identified. The investigation of KRAS status was performed in 94.3% patients, and of these 94.7% had wt KRAS gene. The investigation was performed on primary tumour (83.0%), on metastases (16.0%) or both (1.0%). The main reasons of absence of KRAS status investigation were: previous treatment by cetuximab (63.4%) and absence of available tumour material or technical issue with analysis (26.8%). Investigation of EGFR expression was performed for only 2.4% patients. Cetuximab was mainly prescribed in mCRC (97.9%): 34.5% as first-line therapy, 34.1% as second-line, 21.4% as third-line and 9.6% as fourth-line or more. Investigation of KRAS and wt status were similar whatever the type of treatment (investigation: between 93.2% and 100.0%; wt status: between 93.6% and 100.0%). Among the 74 mCRC patients treated in first-line: cetuximab was combined with irinotecan-based regimen (61.6%), oxaliplatin-based regimen (37.0%) or FOLFIRINOX (1.4%). Cetuximab was given weekly (31.1%) or every 2 weeks (68.9%). Conclusions: EREBUS is the first post-marketing cohort study conducted in France to describe the usage patterns of cetuximab. Extensive investigation of KRAS status and the high proportion of patients with wt status indicates adherence to market authorisation, although EGFR expression remains rarely investigated.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e14094
Use of cetuximab in a real-life setting in France with respect to KRAS status: Preliminary results of EREBUS cohort study.
E14094 Background: Cetuximab demonstrated survival outcome improvement in metastatic colorectal cancer (mCRC). Cetuximab was first launched as a second-line therapy in mCRC. In July 2008, this indication was extended to first-line therapy and restricted to mCRC patients with wild-type (wt) KRAS gene. We present here the preliminary results of the French EREBUS cohort study to describe cetuximab prescription patterns according to KRAS status in a real-life setting. Methods: EREBUS is a cohort study conducted in 93 French centres. Patients initiating cetuximab between Jan and Dec 2009 were identified from nominative hospital pharmacy dispensations. The cohort included mCRC patients treated in first-line were followed for 12 months to evaluate the rate of metastases resection, usage patterns, safety and effectiveness of cetuximab. Results: To date, 1044 patients treated by cetuximab for colorectal cancer have been identified. The investigation of KRAS status was performed in 94.3% patients, and of these 94.7% had wt KRAS gene. The investigation was performed on primary tumour (83.0%), on metastases (16.0%) or both (1.0%). The main reasons of absence of KRAS status investigation were: previous treatment by cetuximab (63.4%) and absence of available tumour material or technical issue with analysis (26.8%). Investigation of EGFR expression was performed for only 2.4% patients. Cetuximab was mainly prescribed in mCRC (97.9%): 34.5% as first-line therapy, 34.1% as second-line, 21.4% as third-line and 9.6% as fourth-line or more. Investigation of KRAS and wt status were similar whatever the type of treatment (investigation: between 93.2% and 100.0%; wt status: between 93.6% and 100.0%). Among the 74 mCRC patients treated in first-line: cetuximab was combined with irinotecan-based regimen (61.6%), oxaliplatin-based regimen (37.0%) or FOLFIRINOX (1.4%). Cetuximab was given weekly (31.1%) or every 2 weeks (68.9%). Conclusions: EREBUS is the first post-marketing cohort study conducted in France to describe the usage patterns of cetuximab. Extensive investigation of KRAS status and the high proportion of patients with wt status indicates adherence to market authorisation, although EGFR expression remains rarely investigated.
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 555
Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study.
555 Background: In view of the ageing population, oncogeriatrics has become a priority for public health. Elderly cancer patients are often excluded from clinical trials and there is no therapeutic standard for their care management. Cohort studies have been conducted in US and Europe but not in France. The ETNA study aimed to describe BV use and survival outcomes in real-life practice. Here, the population aged >75 years was compared to that aged >75. Methods: ETNA is a cohort study conducted in 28 French centers that included 411 patients initiating BV between Jan 2006 and Dec 2007, with 24 month follow-up. Results: Fifty-one patients (12.4%) of the cohort were over 75 years old: mean age 78.3 years (vs 61.9 years for the rest of the cohort), male 66.7% (vs 56.1%), ECOG≥2 17.6% (vs 10.8%). BV was combined with FOLFIRI/XELIRI in 88.2% of patients aged >75 years (vs 87.5%) and FOLFOX/XELOX in 11.8% (vs 12.2%). Median duration of BV treatment was 5.6 months (m) (vs 5.5 m), and median duration of the 1st-line was 10.3 m (vs 9.8 m). More patients >75 years had treatment-free intervals (39.2% vs 28.6%), and 13.7% had a maintenance therapy (vs 12.8%). Curative surgery performed in 15.7% of patients (vs. 20.6%). Among the 43 patients who discontinued the 1st-line, only 9.3% discontinued BV prematurely (vs 18.2%). The incidence of any grade-3/4 adverse event was 43.1% (vs 41.7%). In-line with the known safety profile of BV (any grade), hypertension was observed in 21.6% (vs 18.9%), proteinuria 23.5% (vs 27.2%), there were no GI perforations (vs 0.3%), thrombotic events 5.9% (vs 7.8%), and grade 3/4 arterial thrombotic events 2.0% (vs 0.6%). The 1-year OS rate was 78.0%, 95%CI [63.9-87.2] (vs 80.5%, 95%CI [76.0-84.2]) and the median OS was not reached for both groups. The median PFS was 10.6 m, 95%CI [9.0-12.8] (vs 9.9 m, 95%CI [9.3-11.1]). Conclusions: Effectiveness and safety of BV plus chemotherapy in elderly patients were similar to those of the rest of the ETNA cohort. Estimations of survival outcomes (1-year OS rate, median OS and PFS) were also comparable to those found in elderly patients (75-80 years) from the BRITE cohort (72.0%, 20.3 m and 10.0 m, respectively). No significant financial relationships to disclose.
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 555
Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study.
555 Background: In view of the ageing population, oncogeriatrics has become a priority for public health. Elderly cancer patients are often excluded from clinical trials and there is no therapeutic standard for their care management. Cohort studies have been conducted in US and Europe but not in France. The ETNA study aimed to describe BV use and survival outcomes in real-life practice. Here, the population aged >75 years was compared to that aged >75. Methods: ETNA is a cohort study conducted in 28 French centers that included 411 patients initiating BV between Jan 2006 and Dec 2007, with 24 month follow-up. Results: Fifty-one patients (12.4%) of the cohort were over 75 years old: mean age 78.3 years (vs 61.9 years for the rest of the cohort), male 66.7% (vs 56.1%), ECOG≥2 17.6% (vs 10.8%). BV was combined with FOLFIRI/XELIRI in 88.2% of patients aged >75 years (vs 87.5%) and FOLFOX/XELOX in 11.8% (vs 12.2%). Median duration of BV treatment was 5.6 months (m) (vs 5.5 m), and median duration of the 1st-line was 10.3 m (vs 9.8 m). More patients >75 years had treatment-free intervals (39.2% vs 28.6%), and 13.7% had a maintenance therapy (vs 12.8%). Curative surgery performed in 15.7% of patients (vs. 20.6%). Among the 43 patients who discontinued the 1st-line, only 9.3% discontinued BV prematurely (vs 18.2%). The incidence of any grade-3/4 adverse event was 43.1% (vs 41.7%). In-line with the known safety profile of BV (any grade), hypertension was observed in 21.6% (vs 18.9%), proteinuria 23.5% (vs 27.2%), there were no GI perforations (vs 0.3%), thrombotic events 5.9% (vs 7.8%), and grade 3/4 arterial thrombotic events 2.0% (vs 0.6%). The 1-year OS rate was 78.0%, 95%CI [63.9-87.2] (vs 80.5%, 95%CI [76.0-84.2]) and the median OS was not reached for both groups. The median PFS was 10.6 m, 95%CI [9.0-12.8] (vs 9.9 m, 95%CI [9.3-11.1]). Conclusions: Effectiveness and safety of BV plus chemotherapy in elderly patients were similar to those of the rest of the ETNA cohort. Estimations of survival outcomes (1-year OS rate, median OS and PFS) were also comparable to those found in elderly patients (75-80 years) from the BRITE cohort (72.0%, 20.3 m and 10.0 m, respectively). No significant financial relationships to disclose.
- 1 October 2010
- Published by Elsevier in Bulletin du Cancer
- Vol. 97 (4) , S67-S68
R131 Chirurgie des métastases après traitement en première ligne du cancer colorectal par bévacizumab : résultats de la cohorte ETNA
- 1 October 2010
- Published by Elsevier in Bulletin du Cancer
- Vol. 97 (4) , S67-S68
R131 Chirurgie des métastases après traitement en première ligne du cancer colorectal par bévacizumab : résultats de la cohorte ETNA
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 3594
Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study.
3594 Background: BV associated with chemotherapy has been demonstrated to improve overall survival (OS) in metastatic CRC (mCRC). This allows to consider secondary resection of metastases for the initially unresectable mCRC. Methods: ETNA is a cohort study conducted in 28 French centers. It included patients (pts) initiating BV from Jan 2006 to Dec 2007. Those treated in first-line therapy for mCRC were followed for 24 months. Effectiveness for pats with secondary resection of metastases and curative intent is presented here. Results: A total of 411 pts had first-line therapy with BV for mCRC: 347 were analyzable after 24 months of follow-up, and 67 (19.3%) had metastasis resection (pts operated, oPts). oPts main baseline characteristics were: mean age: 61.6 y, male: 46.3%, ECOG 0-1: 91.0% and one metastatic site: 58.2%; those of not operated pts (noPts) were: mean age: 64.0 y, male: 60.0%, ECOG 0-1: 77.5% and one metastatic site: 55.7%. Among the oPts, resection site was: liver n = 44, lung n = 10, other n = 20. Results of surgery available for 56 oPts were: R0-R1: 85.7%, R2: 14.3%. The median time from BV initiation to first resection was 207 days. For oPts, BV was mainly associated with irinotecan-based regimens (97.0%) and with FOLFOX regimens (3.0%); for noPts it was: FOLFIRI: 83.6%, XELIRI: 2.9%, FOLFOX: 10.7%, XELOX: 2.5% and FOLFIRINOX: 0.4%. Objective response rate was 85.1% including 32.8% complete response (vs. 49.3% and 5.4% for noPts), stable disease 14.9% (vs. 30.0%) and absence of progressive disease (vs. 17.1%). Median duration of BV treatment was 6.9 months and of first-line therapy was 14.3 months (vs. 5.0 and 8.3 months for noPts). Median PFS was 13.6 months for oPts, the 1-yr OS rate was 94.0% (95%CI 84.9-97.7) and the 2-yr OS rate was 81.7% (95%CI 70.0-89.2) (vs. for noPts: median PFS 9.0 months, 1-yr OS rate 75.2% [95%CI 69.6-79.8] and the 2-yr OS rate 44.5% [95%CI 38.5-50.4]). Median OS was not reached for oPts and was 21.9 months for noPts. Conclusions: For pts treated by BV in a real-life setting, secondary resection of mCRC for initially unresectable metastases was possible for 19% of pts with 85.7% R0-R1. Evaluation of morbidity and longer follow-up will allow the real long-term benefit to be studied. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 3594
Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study.
3594 Background: BV associated with chemotherapy has been demonstrated to improve overall survival (OS) in metastatic CRC (mCRC). This allows to consider secondary resection of metastases for the initially unresectable mCRC. Methods: ETNA is a cohort study conducted in 28 French centers. It included patients (pts) initiating BV from Jan 2006 to Dec 2007. Those treated in first-line therapy for mCRC were followed for 24 months. Effectiveness for pats with secondary resection of metastases and curative intent is presented here. Results: A total of 411 pts had first-line therapy with BV for mCRC: 347 were analyzable after 24 months of follow-up, and 67 (19.3%) had metastasis resection (pts operated, oPts). oPts main baseline characteristics were: mean age: 61.6 y, male: 46.3%, ECOG 0-1: 91.0% and one metastatic site: 58.2%; those of not operated pts (noPts) were: mean age: 64.0 y, male: 60.0%, ECOG 0-1: 77.5% and one metastatic site: 55.7%. Among the oPts, resection site was: liver n = 44, lung n = 10, other n = 20. Results of surgery available for 56 oPts were: R0-R1: 85.7%, R2: 14.3%. The median time from BV initiation to first resection was 207 days. For oPts, BV was mainly associated with irinotecan-based regimens (97.0%) and with FOLFOX regimens (3.0%); for noPts it was: FOLFIRI: 83.6%, XELIRI: 2.9%, FOLFOX: 10.7%, XELOX: 2.5% and FOLFIRINOX: 0.4%. Objective response rate was 85.1% including 32.8% complete response (vs. 49.3% and 5.4% for noPts), stable disease 14.9% (vs. 30.0%) and absence of progressive disease (vs. 17.1%). Median duration of BV treatment was 6.9 months and of first-line therapy was 14.3 months (vs. 5.0 and 8.3 months for noPts). Median PFS was 13.6 months for oPts, the 1-yr OS rate was 94.0% (95%CI 84.9-97.7) and the 2-yr OS rate was 81.7% (95%CI 70.0-89.2) (vs. for noPts: median PFS 9.0 months, 1-yr OS rate 75.2% [95%CI 69.6-79.8] and the 2-yr OS rate 44.5% [95%CI 38.5-50.4]). Median OS was not reached for oPts and was 21.9 months for noPts. Conclusions: For pts treated by BV in a real-life setting, secondary resection of mCRC for initially unresectable metastases was possible for 19% of pts with 85.7% R0-R1. Evaluation of morbidity and longer follow-up will allow the real long-term benefit to be studied. No significant financial relationships to disclose.